Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lupin Slumps To Q4 Loss Amid US Opioid Action But Build Up In Inhalation, Biosimilars

Executive Summary

Lupin ended the fourth quarter in the red hit by an impairment provision related to the "underperforming" assets of its Gavis acquisition but the firm's US inhalation pipeline appears to have made some progress, including a filing for tiotropium dry powder inhaler (DPI). Early stage biosimilars under development include, among others, versions of Neulasta and Xgeva/Prolia.

Advertisement

Related Content

India Pharma Q1 Preview: Home Gains But Subdued US Growth
Profile: Lupin CFO Swaminathan, The ‘Constant Learner'
Deal Watch Asia Focus: Merck Partners With Alibaba For Entry To Digital Health In China
Opioid Legislation Would Require US FDA Guidance On Non-Opioid Pain Medication Development
Lupin In Tailspin After Two-In-One FDA Warning Letter
Lupin Primes For Specialty Future With Symbiomix Acquisition

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel